- Home
- NEN vs ADCT Comparison
NEN vs ADCT Comparison
Compare NEN & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- ADCT
- Stock Information
- Founded
- NEN 1977
- ADCT 2011
- Country
- NEN United States
- ADCT Switzerland
- Employees
- NEN N/A
- ADCT N/A
- Industry
- NEN Building operators
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- ADCT Health Care
- Exchange
- NEN Nasdaq
- ADCT Nasdaq
- Market Cap
- NEN 262.4M
- ADCT 241.0M
- IPO Year
- NEN N/A
- ADCT 2020
- Fundamental
- Price
- NEN $72.49
- ADCT $2.69
- Analyst Decision
- NEN
- ADCT Strong Buy
- Analyst Count
- NEN 0
- ADCT 6
- Target Price
- NEN N/A
- ADCT $7.80
- AVG Volume (30 Days)
- NEN 450.0
- ADCT 663.5K
- Earning Date
- NEN 01-01-0001
- ADCT 08-12-2025
- Dividend Yield
- NEN 6.62%
- ADCT N/A
- EPS Growth
- NEN 58.97
- ADCT N/A
- EPS
- NEN 4.56
- ADCT N/A
- Revenue
- NEN $82,531,485.00
- ADCT $75,817,000.00
- Revenue This Year
- NEN N/A
- ADCT $11.75
- Revenue Next Year
- NEN N/A
- ADCT $8.56
- P/E Ratio
- NEN $15.89
- ADCT N/A
- Revenue Growth
- NEN 6.12
- ADCT 10.49
- 52 Week Low
- NEN $68.98
- ADCT $1.05
- 52 Week High
- NEN $84.00
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- NEN 37.80
- ADCT 40.85
- Support Level
- NEN $72.26
- ADCT $2.84
- Resistance Level
- NEN $73.44
- ADCT $3.19
- Average True Range (ATR)
- NEN 0.16
- ADCT 0.19
- MACD
- NEN -0.01
- ADCT -0.06
- Stochastic Oscillator
- NEN 13.22
- ADCT 12.66
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).